Talk:Charles Lapp

New content

The following content kindly contributed by User:DoctorLapp should be merged in with the existing Charles Lapp page. ~Njt (talk) 00:36, October 26, 2020 (UTC)

Brief Resumé of Charles W. Lapp, M.D. Hunter-Hopkins Center, Charlotte, NC

Dr. Lapp has practiced internal medicine and pediatrics in North Carolina since 1978, and began researching CFS and FM in 1985 following an epidemic in Raleigh. He has had over 30 years of experience treating these disorders, and has been Assisting Consulting Professor of Community and Family Medicine at Duke University from 1982-2016.

He is active in both civic and professional activities. He is a diplomate of the American Board of Internal Medicine, and a Fellow of the American Academy of Family Practice, the American Academy of Pediatrics, and the American Board of Independent Medical Examiners.

Dr. Lapp has been a consultant to the Centers for Disease Control and was tapped by Secretary Tommy Thompson of the Department of Health & Human Services to advise the federal government on CFS-related issues.

Dr. Lapp has written numerous articles and has spoken widely. He co-authored the Center for Disease Control Provider Program on Chronic Fatigue Syndrome, several book chapters on CFS/FM, a section on disability for Lexus-Nexus, the IACFS “Primer for Clinical Practitioners,” “A Framework for Fibromyalgia Management,” as well as two MedScape programs on diagnosing and treating CFS. He was a reviewer for the National Academies of Medicine IOM report (2015), “Beyond Myalgic Encephalopathy and Chronic Fatigue Syndrome: Redefining an Illness.”

He has been the medical advisor to the Chronic Fatigue Syndrome Association of America, the American Fibromyalgia Syndrome Association, and the National Fibromyalgia Association; and a board member of the International Association for CFS and FM (IACFS).

Dr. Lapp has also served as primary research investigator and speaker for Pfizer (Lyrica), Lilly (Cymbalta), Forest (Savella), Cephalon (Provigil), Hemispherx (Ampligen), Pro Health (Transfer Factor) , and several other pharmaceutical companies. He has produced national webcasts for Pfizer, and served as a fibromyalgia consultant for Pfizer.

Dr. Lapp is currently the Medical Director of the Hunter-Hopkins Center in Charlotte, North Carolina. Hunter-Hopkins Center is one of the few medical practices in the United States to specialize in treating CFS, FM, and related disorders.

Complete Curriculum Vitae can be viewed at http://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/

Centers for Disease Control and Prevention (CDC) - The Centers for Disease Control and Prevention is a U.S. government agency dedicated to epidemiology and public health. It operates under the auspices of the Department of Health and Human Services.

Centers for Disease Control and Prevention (CDC) - The Centers for Disease Control and Prevention is a U.S. government agency dedicated to epidemiology and public health. It operates under the auspices of the Department of Health and Human Services.

Institute of Medicine report (IOM report) - A report that was commissioned by the U.S. government and was published by the Institute of Medicine on February 10, 2015. The report was titled "Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness" and proposed the term Systemic Exertion Intolerance Disease (SEID). Among its key findings were that "This disease is characterized by profound fatigue, cognitive dysfunction, sleep abnormalities, autonomic manifestations, pain, and other symptoms that are made worse by exertion of any sort." The report further stated "Between 836,000 and 2.5 million Americans suffer from myalgic encephalomyelitis/chronic fatigue syndrome."

myalgic encephalopathy An alternate term that is sometimes used for myalgic encephalomyelitis, by people who believe the evidence for inflammation in ME is insufficient. This terminology reflects the belief that the "-itis" suffix implies inflammation.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.